Join Growin Stock Community!

華宇藥6621.TW Overview

TW StockBiotech. & Medical
(No presentation for 6621)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

華宇藥（6621）Overall Performance

華宇藥（6621）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

華宇藥（6621） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

華宇藥（6621）Key Information

華宇藥（6621）Profile

UniPharma Co., Ltd. engages in the distribution of pharmaceutical drugs, medical devices, and diagnostic tests in Taiwan. The company provides diagnostic tests in areas of oncology, gynecology, orthopedics, neurology, anesthesiology, and cardiology. It offers Adept reduction solution; bain, esmolol HCI, and naloxone anesthesia injections; Elisa DR-70 test for in-vitro diagnostics of tumors; and fomeject antidote injection, as well as drug development, research and development, clinical trials, marketing, and other business services. It serves medical centers, regional and area hospitals, and clinics. UniPharma Co., Ltd. was incorporated in 1998 and is based in Taipei, Taiwan.

華宇藥（6621）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.84
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
2.24
PB Ratio
1.70
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
49.61%
Net Margin
-34.29%
Revenue Growth (YoY)
-20.06%
Profit Growth (YoY)
-32.12%
3-Year Revenue Growth
-16.02%
3-Year Profit Growth
-10.46%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.84
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
2.24
PB Ratio
1.70
Price-to-FCF
-
Gross Margin
49.61%
Net Margin
-34.29%
Revenue Growth (YoY)
-20.06%
Profit Growth (YoY)
-32.12%
3-Year Revenue Growth
-16.02%
3-Year Profit Growth
-10.46%
default symbol

6621

華宇藥

12.00D

-2.92%

(-0.03)

  • When is 6621's latest earnings report released?

    The most recent financial report for 華宇藥 (6621) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6621's short-term business performance and financial health. For the latest updates on 6621's earnings releases, visit this page regularly.

  • What is the operating profit of 6621?

    According to the latest financial report, 華宇藥 (6621) reported an Operating Profit of -23.21M with an Operating Margin of -52.38% this period, representing a decline of 65.77% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 6621's revenue growth?

    In the latest financial report, 華宇藥 (6621) announced revenue of 44.32M, with a Year-Over-Year growth rate of -5.68%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 6621 have?

    At the end of the period, 華宇藥 (6621) held Total Cash and Cash Equivalents of 46.12M, accounting for 0.16 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6621 go with three margins increasing?

    In the latest report, 華宇藥 (6621) did not achieve the “three margins increasing” benchmark, with a gross margin of 52.74%%, operating margin of -52.38%%, and net margin of -53.73%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6621's profit trajectory and future growth potential.

  • Is 6621's EPS continuing to grow?

    According to the past four quarterly reports, 華宇藥 (6621)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.67. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 6621?

    華宇藥 (6621)'s Free Cash Flow (FCF) for the period is -16.29M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 277.17% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.